KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Leases: 2019-2024

Historic Operating Leases for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Dec 2024 value amounting to $34.3 million.

  • Supernus Pharmaceuticals' Operating Leases rose 10.64% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 10.64%. This contributed to the annual value of $34.3 million for FY2024, which is 17.47% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Operating Leases stood at $34.3 million for FY2024, which was down 17.47% from $41.5 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Operating Leases high stood at $56.3 million for FY2020, and its period low was $34.3 million during FY2024.
  • Moreover, its 3-year median value for Operating Leases was $41.5 million (2023), whereas its average is $39.5 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Operating Leases spiked by 69.35% in 2020, and later declined by 17.47% in 2024.
  • Supernus Pharmaceuticals' Operating Leases (Yearly) stood at $56.3 million in 2020, then declined by 15.19% to $47.8 million in 2021, then dropped by 10.44% to $42.8 million in 2022, then fell by 2.95% to $41.5 million in 2023, then declined by 17.47% to $34.3 million in 2024.